CCCC250117P1000
- 0.00
- 0.000.00%
C4 Therapeutics Newsroom
Wells Fargo Upgrades C4 Therapeutics(CCCC.US) to Buy Rating, Raises Target Price to $12
C4 Therapeutics Analyst Ratings
Wells Fargo Upgrades C4 Therapeutics to Overweight, Raises Price Target to $12
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating
Stephens & Co. Initiates Coverage On C4 Therapeutics With Equal-Weight Rating, Announces Price Target of $4
C4 Therapeutics Analyst Ratings
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Morgan Stanley Keeps Their Hold Rating on C4 Therapeutics (CCCC)
BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20
BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
Stifel Nicolaus Keeps Their Buy Rating on C4 Therapeutics (CCCC)
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
Hold Rating on C4 Therapeutics Amid Early-Stage Drug Development and Market Caution
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
BMO Capital Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $20
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14